Market Overview:
The global dendritic cell and tumor cell cancer vaccine market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of cancer, rising demand for personalized medicines, and technological advancements in the field of cancer vaccines. Based on type, the global dendritic cell and tumor cell cancer vaccine market can be segmented into CD 4, CD 8, HER-2, T-helper cells (Th1), and others. The CD 4 segment is expected to account for a major share of the global market during the forecast period. This can be attributed to increasing research on targeted therapies that specifically target CD 4+ T cells in patients with various types of cancers. Based on application, the global dendritic cell and tumor cell cancer vaccine market can be divided into glioblastoma cancer, prostate cancer, pancreatic cancer colorectalcancer renalcancer lungcancerand others.
Product Definition:
A dendritic cell (DC) is a type of white blood cell that is important in the immune system. Dendritic cells are found in tissues throughout the body, including in the skin, nose, lungs, and gut. They act as "connectors" between other white blood cells and T cells (a type of lymphocyte). Dendritic cells play a key role in activating T cells to fight infection or cancer.
A tumor cell vaccine is made from a patient's own tumor tissue. The vaccine contains special proteins called antigens that are found on the surface of tumor cells. These antigens can be used to help activate the patient's immune system to destroy cancer tumors.
CD 4:
CD4 is a protein that acts as an important part of the immune system. The number of CD4 cells in the body is normally present between 350 and 2,500 per mm3 of blood. In response to an antigen, these cells migrate from the lymphoid tissue towards the site of infection and help initiate an immune response by releasing cytokines and other chemicals known as chemokines.
CD 8:
CD8 is also known as T-cell receptor cell, it is a type of white blood cell that provides the immune response against viruses and bacteria. The CD8+ cells are involved in the recognition and killing of infected cells by way of a process called immuno-editing. These cells belong to the B-cell family and are produced in the bone marrow and include both prokaryotic (BK) as well as eukaryotic (mammalian) types.
Application Insights:
The global demand for dendritic cell and tumor cell cancer vaccine is expected to be driven by the growing incidence of glioblastoma, prostate cancer, pancreatic cancer, colorectal cancer and renal carcinoma. The increasing prevalence of these cancers across the globe is anticipated to boost market growth during the forecast period.
Glioblastoma was estimated as the most aggressive type of brain tumor in 2015 due to its resistance towards chemotherapy and radiation therapy which prompted researchers around the world to develop novel therapeutic strategies for its treatment. Glioblastoma multiforme is also known as astrocytomas or GBM for shortand accounts for 10%to15%of all primary brain tumors diagnosed each year globally. It predominantly affects elderly people with a cumulative riskof developing this disease after 50 years of age ranging from 2%to 5%.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, increasing investment by these companies and government support for research activities. For instance, in November 2018, Pfizer Inc., a U.S.-based pharmaceutical company announced funding worth USD X million to The Institute for Cancer Research and The Leukemia & Lymphoma Society towards research activities related to dendritic cell-based immunotherapy for cancer treatment.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising awareness about various types of vaccines among patients as well as healthcare professionals along with increasing investments by major vaccine manufacturers in this region which has resulted into high demand for these vaccines from this region. In addition, growing incidence rates of cancer are also anticipated boost revenue generation from this region during the forecast period (2018-2030).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the dendritic cell and tumor cell cancer vaccine market. According to the American Cancer Society, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S., and approximately 595,690 people died from this disease. This number is expected to rise in the coming years due to increasing aging population and lifestyle-related risk factors such as obesity and smoking.
- Growing demand for personalized medicine: The growing demand for personalized medicine is another key growth driver for this market. Dendritic cells are highly personalized cells that can be customized according to individual patient’s needs. This makes them an ideal candidate for developing targeted therapies against various cancers.
- Janssen Biotech announced a collaboration with MD Anderson Cancer Center to develop novel immunotherapies using dendritic cells derived from patients’ tumors or blood samples . Such collaborations are likely to result in innovations that will drive further growth of this market in future years..
Scope Of The Report
Report Attributes
Report Details
Report Title
Dendritic Cell and Tumor Cell Cancer Vaccine Market Research Report
By Type
CD 4, CD 8, HER-2, T-helper cell, Others,
By Application
Glioblastoma Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer, Renal Cancer, Lung Cancer, Others,
By Companies
JW CreaGene, Miltenyi Biotec, GlaxoSmithKline, NorthWest BioTherapeutics, ImmunoCellular Therapeutics, EnoChian Bioscience, Medigene, Tella Incorporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Report Segments:
The global Dendritic Cell and Tumor Cell Cancer Vaccine market is segmented on the basis of:
Types
CD 4, CD 8, HER-2, T-helper cell, Others,
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Glioblastoma Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer, Renal Cancer, Lung Cancer, Others,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- JW CreaGene
- Miltenyi Biotec
- GlaxoSmithKline
- NorthWest BioTherapeutics
- ImmunoCellular Therapeutics
- EnoChian Bioscience
- Medigene
- Tella Incorporation
Highlights of The Dendritic Cell and Tumor Cell Cancer Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CD 4
- CD 8
- HER-2
- T-helper cell
- Others
- By Application:
- Glioblastoma Cancer
- Prostate Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Renal Cancer
- Lung Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dendritic Cell and Tumor Cell Cancer Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dendritic cell (DC) vaccines are designed to help prevent cancer by stimulating the body's natural defenses against tumor cells. Tumor cell cancer vaccines use a patient's own tumor cells as the vaccine target, which is thought to make them more effective and less likely to cause side effects.
Some of the major companies in the dendritic cell and tumor cell cancer vaccine market are JW CreaGene, Miltenyi Biotec, GlaxoSmithKline, NorthWest BioTherapeutics, ImmunoCellular Therapeutics, EnoChian Bioscience, Medigene, Tella Incorporation.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Dendritic Cell and Tumor Cell Cancer Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Dendritic Cell and Tumor Cell Cancer Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Dendritic Cell and Tumor Cell Cancer Vaccine Market - Supply Chain
4.5. Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Forecast
4.5.1. Dendritic Cell and Tumor Cell Cancer Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Dendritic Cell and Tumor Cell Cancer Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Dendritic Cell and Tumor Cell Cancer Vaccine Market Absolute $ Opportunity
5. Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Type
5.3.1. CD 4
5.3.2. CD 8
5.3.3. HER-2
5.3.4. T-helper cell
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Application
6.3.1. Glioblastoma Cancer
6.3.2. Prostate Cancer
6.3.3. Pancreatic Cancer
6.3.4. Colorectal Cancer
6.3.5. Renal Cancer
6.3.6. Lung Cancer
6.3.7. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Dendritic Cell and Tumor Cell Cancer Vaccine Demand Share Forecast, 2019-2026
9. North America Dendritic Cell and Tumor Cell Cancer Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Application
9.4.1. Glioblastoma Cancer
9.4.2. Prostate Cancer
9.4.3. Pancreatic Cancer
9.4.4. Colorectal Cancer
9.4.5. Renal Cancer
9.4.6. Lung Cancer
9.4.7. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Type
9.7.1. CD 4
9.7.2. CD 8
9.7.3. HER-2
9.7.4. T-helper cell
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Dendritic Cell and Tumor Cell Cancer Vaccine Demand Share Forecast, 2019-2026
10. Latin America Dendritic Cell and Tumor Cell Cancer Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Application
10.4.1. Glioblastoma Cancer
10.4.2. Prostate Cancer
10.4.3. Pancreatic Cancer
10.4.4. Colorectal Cancer
10.4.5. Renal Cancer
10.4.6. Lung Cancer
10.4.7. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Type
10.7.1. CD 4
10.7.2. CD 8
10.7.3. HER-2
10.7.4. T-helper cell
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Dendritic Cell and Tumor Cell Cancer Vaccine Demand Share Forecast, 2019-2026
11. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Application
11.4.1. Glioblastoma Cancer
11.4.2. Prostate Cancer
11.4.3. Pancreatic Cancer
11.4.4. Colorectal Cancer
11.4.5. Renal Cancer
11.4.6. Lung Cancer
11.4.7. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Pojections by Application
11.7. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Type
11.7.1. CD 4
11.7.2. CD 8
11.7.3. HER-2
11.7.4. T-helper cell
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Demand Share, 2019-2026
12. Asia Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Application
12.4.1. Glioblastoma Cancer
12.4.2. Prostate Cancer
12.4.3. Pancreatic Cancer
12.4.4. Colorectal Cancer
12.4.5. Renal Cancer
12.4.6. Lung Cancer
12.4.7. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Type
12.7.1. CD 4
12.7.2. CD 8
12.7.3. HER-2
12.7.4. T-helper cell
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Demand Share, 2019-2026
13. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Application
13.4.1. Glioblastoma Cancer
13.4.2. Prostate Cancer
13.4.3. Pancreatic Cancer
13.4.4. Colorectal Cancer
13.4.5. Renal Cancer
13.4.6. Lung Cancer
13.4.7. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Volume Forecast by Type
13.7.1. CD 4
13.7.2. CD 8
13.7.3. HER-2
13.7.4. T-helper cell
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Dendritic Cell and Tumor Cell Cancer Vaccine Market: Market Share Analysis
14.2. Dendritic Cell and Tumor Cell Cancer Vaccine Distributors and Customers
14.3. Dendritic Cell and Tumor Cell Cancer Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. JW CreaGene
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Miltenyi Biotec
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GlaxoSmithKline
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. NorthWest BioTherapeutics
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. ImmunoCellular Therapeutics
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. EnoChian Bioscience
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Medigene
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Tella Incorporation
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
&n
